Orexigen Therapeutics, Inc. announced today that it recently met with the Food and Drug Administration (FDA) regarding the New Drug Application for Contrave (naltrexone HCl/bupropion HCl) extended-release tablets for the treatment of obesity, including we
Phillip Sinaikin, M.D. is a Florida psychiatrist who has been in practice for 25 years. "Psychiatryland," his new book, focuses on excesses and industry influence in the field of psychiatry.
TUESDAY, Dec. 7 (HealthDay News) -- An expert advisory panel recommended on Tuesday that Contrave, a new weight-loss pill that combines an antidepressant with an anti-addiction medication, be approved by the U.S. Food and Drug Administration.
Empowered patient: If you've never really experienced depression, it's hard to understand what it's like. Tobin Levy shares her downward spiral from thriving magazine writer to suicidal wreck - and how she's navigating her way to a brighter tomorrow.